login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MBX BIOSCIENCES INC (MBX) Stock News
USA
- NASDAQ:MBX -
US55287L1017
-
Common Stock
14.23
USD
+1.01 (+7.64%)
Last: 10/20/2025, 8:01:12 PM
14.63
USD
+0.4 (+2.81%)
Pre-Market:
10/21/2025, 8:58:59 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MBX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: MBX Biosciences, Inc.
MBX Biosciences to Participate in November Investor Conferences
a month ago - By: Benzinga
- Mentions:
RIG
CAN
GALT
BE
...
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
a month ago - By: Benzinga
- Mentions:
RAYA
ZVRA
RIG
WOK
...
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
a month ago - By: Investor's Business Daily
MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise
a month ago - By: Stocktwits
MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study
2 months ago - By: The Motley Fool
Mbx Biosciences (MBX) Q2 Loss Widens 22%
a month ago - By: MBX Biosciences, Inc.
MBX Biosciences Announces Pricing of Upsized Public Offering
a month ago - By: MBX Biosciences, Inc.
MBX Biosciences Announces Proposed Public Offering
a month ago - By: MBX Biosciences, Inc.
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
a month ago - By: MBX Biosciences, Inc.
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
2 months ago - By: MBX Biosciences, Inc.
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
3 months ago - By: MBX Biosciences, Inc.
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
4 months ago - By: MBX Biosciences, Inc.
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
4 months ago - By: MBX Biosciences, Inc.
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
5 months ago - By: MBX Biosciences, Inc.
MBX Biosciences to Participate in June Investor Conferences
5 months ago - By: MBX Biosciences, Inc.
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
6 months ago - By: MBX Biosciences, Inc.
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
7 months ago - By: MBX Biosciences, Inc.
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
Please enable JavaScript to continue using this application.